Posted by Michael Wonder on 05 Jun 2018
NICE rules against first-line use of Ipsen’s Cabometyx
5 June 2018 - NICE has issued a preliminary decision rejecting first-line use of Ipsen/Exelixis’ Cabometyx in renal cancer on the NHS.
Cabometyx (cabozantinib) is currently routinely available on the NHS as a treatment for adult patients with advanced RCC following prior vascular endothelial growth factor (VEGF)-targeted therapy.
Earlier this year, the drug’s scope was expanded in Europe to include treatment-naïve adults with advanced RCC, on the back of data showing patients given Cabometyx had a median progression free survival of 8.6 months versus 5.3 months for those treated initially with sunitinib (Pfizer’s Sutent), marking a 52 percent reduction in the hazard for progression or death.
